QCG
GMAB icon

Quadrant Capital Group’s Genmab GMAB Stock Holding History

Quadrant Capital Group’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Buy
22,457
+500
+2% +$13.3K 0.02% 782
2026
Q1 		$589K Sell
21,957
-439
-2% -$13.2K 0.02% 826
2025
Q4 		$690K Sell
22,396
-477
-2% -$14.9K 0.02% 755
2025
Q3 		$702K Sell
22,873
-4,645
-17% -$113K 0.02% 687
2025
Q2 		$569K Sell
27,518
-2,245
-8% -$46.1K 0.02% 793
2025
Q1 		$583K Buy
29,763
+13,248
+80% +$278K 0.02% 638
2024
Q4 		$345K Buy
16,515
+8,245
+100% +$181K 0.02% 449
2024
Q3 		$202K Buy
8,270
+1,962
+31% +$52.5K 0.01% 689
2024
Q2 		$159K Sell
6,308
-569
-8% -$16.1K 0.01% 760
2024
Q1 		$206K Sell
6,877
-42
-0.6% -$1.23K 0.02% 609
2023
Q4 		$220K Sell
6,919
-2,851
-29% -$89.5K 0.02% 558
2023
Q3 		$345K Buy
9,770
+2,496
+34% +$95.1K 0.03% 351
2023
Q2 		$276K Buy
7,274
+1,030
+16% +$41.1K 0.03% 410
2023
Q1 		$236K Sell
6,244
-2,462
-28% -$94.6K 0.02% 461
2022
Q4 		$369K Buy
8,706
+1,462
+20% +$60.2K 0.04% 319
2022
Q3 		$233K Buy
7,244
+3,051
+73% +$107K 0.03% 381
2022
Q2 		$136K Sell
4,193
-202
-5% -$6.54K 0.02% 538
2022
Q1 		$159K Sell
4,395
-189
-4% -$6.49K 0.02% 516
2021
Q4 		$181K Sell
4,584
-780
-15% -$32.5K 0.02% 468
2021
Q3 		$234K Buy
5,364
+382
+8% +$17.1K 0.03% 350
2021
Q2 		$203K Sell
4,982
-9
-0.2% -$347 0.03% 381
2021
Q1 		$164K Buy
4,991
+702
+16% +$26.4K 0.03% 404
2020
Q4 		$174K Buy
4,289
+234
+6% +$8.75K 0.03% 342
2020
Q3 		$148K Buy
4,055
+1,680
+71% +$60.7K 0.03% 328
2020
Q2 		$80K Sell
2,375
-10,128
-81% -$276K 0.02% 542
2020
Q1 		$265K Sell
12,503
-1,047
-8% -$23.3K 0.04% 319
2019
Q4 		$296K Buy
13,550
+1,434
+12% +$31.3K 0.04% 509
2019
Q3 		$241K Buy
+12,116
New +$239K 0.04% 519

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrant Capital Group's GMAB Position: Q2 2026 in Review

Quadrant Capital Group increased its Genmab (GMAB) stake by 2.3% in Q2 2026, buying an estimated $13.3K and bringing the position to 22,457 shares worth $617K. The position accounts for 0.02% of the portfolio, ranked #782.

Quadrant Capital Group first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $702K in Q3 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Quadrant Capital Group held 22,457 shares of Genmab worth $617K as of Q2 2026.
  • Quadrant Capital Group bought 500 Genmab shares in Q2 2026, an estimated $13.3K.
  • Genmab made up 0.02% of Quadrant Capital Group's portfolio in Q2 2026, its #782 holding.
  • Quadrant Capital Group first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Quadrant Capital Group's Genmab position peaked at $702K in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.